Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1648192 | 0.79 | CYP2D6 (0.50) | ALDH1A1HSD17B10LMNAKMT2ATDP1 | |
| SCHEMBL3077789 | 0.71 | — | — | |
| SCHEMBL4168577 | 0.69 | ALDH1A1 (0.48) | ALDH1A1 | |
| SCHEMBL1421666 | 0.67 | ALDH1A1 (0.43) | ALDH1A1HSD17B10LMNAKMT2ATDP1 | |
| SCHEMBL28043473 | 0.65 | ALDH1A1 (0.43) | ALDH1A1 | |
| SCHEMBL8104848 | 0.65 | ALDH1A1 (0.50) | ALDH1A1TDP1 | |
| SCHEMBL1845437 | 0.65 | TSHR (0.55) | ALDH1A1HSD17B10LMNAKMT2ATDP1 | |
| SCHEMBL8761436 | 0.65 | TSHR (0.34) | HSD17B10 | |
| SCHEMBL2898744 | 0.64 | DGKA (0.53) | ALDH1A1HSD17B10LMNAKMT2ATDP1 | |
| SCHEMBL29435917 | 0.64 | DGKA (0.53) | ALDH1A1HSD17B10LMNAKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8491929-B2 | Bioadhesive polymers | VAUNNEX INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20110086095-A1 | Bioadhesive Polymers | Spherics, Inc (MA) | 2011-04-14 | — | — | US | disclosed |
| US-20100316712-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS | COMBINATORX, INCORPORATED (US) | 2010-12-16 | — | — | US | disclosed |
| EP-2063867-A2 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS | Combinatorx, Incorporated (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20080299204-A1 | Dosage forms for movement disorder treatment | SPHERICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| WO-2008079404-A2 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080131492-A1 | Dosage forms for movement disorder treatment | SPHERICS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| EP-1901720-A2 | IMPROVED DOSAGE FORMS FOR MOVEMENT DISORDER TREATMENT | Spherics, Inc. (US) | 2008-03-26 | — | — | EP | disclosed |
| WO-2008002471-A2 | EROSION-STABILIZED BIOADHESIVE POLYMERS FUNCTIONALIZED OR BLENDED WITH CATECHOL AND DERIVATIVES THEREOF | SPHERICS, INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20070148238-A1 | Dosage forms for movement disorder treatment | SPHERICS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2007002318-A2 | BIOADHESIVE POLYMERS | SPHERICS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002516-A2 | IMPROVED DOSAGE FORMS FOR MOVEMENT DISORDER TREATMENT | SPHERICS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20070003621-A1 | Dosage forms for movement disorder treatment | SPHERICS, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| US-4471789-A | Aliphatic branched olefin dioxolanes, dithiolanes, and oxathiolanes and uses thereof in augmenting or enhancing the aroma and/or taste of consumable materials | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1984-09-18 | — | — | US | disclosed |
| US-4390462-A | Aliphatic branched olefin dioxolanes, dithiolanes, and oxathiolanes and uses thereof in augmenting or enhancing the aroma and/or taste of consumable materials | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1983-06-28 | — | — | US | disclosed |
| US-4381243-A | Aliphatic branched olefin dioxolanes, dithiolanes, and oxathiolanes and uses thereof in augmenting or enhancing the aroma and/or taste of consumable materials | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1983-04-26 | — | — | US | disclosed |
| US-4379754-A | Aliphatic branched olefin dioxolanes, dithiolanes, and oxathiolanes and uses thereof in augmenting or enhancing the aroma and/or taste of consumable materials | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1983-04-12 | — | — | US | disclosed |
| US-4374998-A | PERFUMES, TASTES | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1983-02-22 | — | — | US | disclosed |
| US-4315952-A | Flavoring with dioxolanes | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1982-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086095-A1 | Bioadhesive Polymers | CD44, EPCAM, ABCG2 | ALDH1A1 161/4885HSD17B10 1542/4885LMNA 1723/4885 |
| US-20100316712-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS | PARK7, SNCA, COMT | ALDH1A1 397/4885HSD17B10 2155/4885LMNA 3192/4885 |
| US-20070148238-A1 | Dosage forms for movement disorder treatment | PARK7, SNCA, HTT | ALDH1A1 673/4885HSD17B10 605/4885LMNA 4133/4885 |
| US-20080131492-A1 | Dosage forms for movement disorder treatment | PARK7, SNCA, HTT | ALDH1A1 673/4885HSD17B10 605/4885LMNA 4133/4885 |
| US-20070003621-A1 | Dosage forms for movement disorder treatment | PARK7, SNCA, HTT | ALDH1A1 673/4885HSD17B10 605/4885LMNA 4133/4885 |
| US-20080299204-A1 | Dosage forms for movement disorder treatment | PARK7, SNCA, HTT | ALDH1A1 673/4885HSD17B10 605/4885LMNA 4133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.